ABSTRACT
The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha synergistically upregulated FAT10 expression in liver and colon cancer cells 10- to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-gamma- and TNF-alpha-dependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.
Subject(s)
Carcinoma, Hepatocellular/genetics , Carcinoma/genetics , Colonic Neoplasms/genetics , Cytokines/pharmacology , Inflammation Mediators/pharmacology , Liver Neoplasms/genetics , Ubiquitins/genetics , Up-Regulation/drug effects , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cells, Cultured , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Humans , Mice , Mice, Inbred C57BL , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Tissue Distribution/drug effects , Ubiquitins/metabolismABSTRACT
Dendritic cells (DC) are professional antigen-presenting cells that activate CTL by presenting MHC class I-restricted peptides that are processed through the proteasome pathway. Previously, we reported that upon DC maturation the synthesis is switched towards the exclusive production of immunoproteasomes containing the active site subunits LMP2, LMP7 and MECL-1. In this study we investigated the mechanism by which proteasome assembly is regulated in mature DC. Quantitative analysis of mRNA expression showed very limited transcriptional induction of LMP7, MECL-1 and UMP1 in mature DC and a moderate mRNA increment for LMP2 and PA28alpha and beta. We investigated a role of PA28alpha/beta in regulating proteasome assembly in DC. PA28alpha/beta coprecipitated with 13S/16S proteasome precursor complexes but associated with mature constitutive and immunoproteasomes to the same extent. Furthermore, we determined the steady-state proteasome subunit composition in DC. Replacement of constitutive proteasomes by immunoproteasomes in maturing DC was very slow and occurred only to a minor extent. Our data suggest that the limited turnover of 20S proteasomes in mature DC probably contributes little to recently reported marked differences in antigen presentation between immature and mature DC and that alternative mechanisms may be responsible for this phenomenon.
Subject(s)
Cysteine Endopeptidases/biosynthesis , Dendritic Cells/physiology , Multienzyme Complexes/biosynthesis , Muscle Proteins , Protein Biosynthesis , Binding Sites , Cysteine Endopeptidases/genetics , Humans , Interferon-gamma/pharmacology , Multienzyme Complexes/genetics , Proteasome Endopeptidase Complex , Protein Subunits , RNA, Messenger/analysis , Up-RegulationABSTRACT
The proteasome is critically involved in the production of MHC class I-restricted T cell epitopes. Proteasome activity and epitope production are altered by IFN-gamma treatment, which leads to a gradual replacement of constitutive proteasomes by immunoproteasomes in vitro. However, a quantitative analysis of changes in the steady state subunit composition of proteasomes during an immune response against viruses or bacteria in vivo has not been reported. Here we show that the infection of mice with lymphocytic choriomeningitis virus or Listeria monocytogenes leads to an almost complete replacement of constitutive proteasomes by immunoproteasomes in the liver within 7 days. Proteasome replacements were markedly reduced in IFN-gamma(-/-) mice, but were only slightly affected in IFN-alphaR(-/-) and perforin(-/-) mice. The proteasome regulator PA28alpha/beta was up-regulated, whereas PA28gamma was reduced in the liver of lymphocytic choriomeningitis virus-infected mice. Proteasome replacements in the liver strongly altered proteasome activity and were unexpected to this extent, since an in vivo half-life of 12 days had been previously assigned to constitutive proteasomes in the liver. Our results suggest that during the peak phase of viral and bacterial elimination the antiviral cytotoxic T lymphocyte response is directed mainly to immunoproteasome-dependent T cell epitopes, which would be a novel parameter for the design of vaccines.
Subject(s)
Arenaviridae Infections/immunology , Cysteine Endopeptidases/chemistry , Listeriosis/immunology , Liver Diseases/immunology , Multienzyme Complexes/chemistry , Animals , Arenaviridae Infections/enzymology , Autoantigens , Cysteine Endopeptidases/genetics , Cysteine Endopeptidases/immunology , Interferon-alpha/physiology , Interferon-gamma/genetics , Interferon-gamma/pharmacology , Interferon-gamma/physiology , Listeriosis/enzymology , Liver Diseases/enzymology , Lymphocytic choriomeningitis virus , Membrane Glycoproteins/genetics , Membrane Glycoproteins/physiology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Multienzyme Complexes/genetics , Multienzyme Complexes/immunology , Nuclear Proteins/metabolism , Perforin , Pore Forming Cytotoxic Proteins , Proteasome Endopeptidase Complex , Protein Biosynthesis , Proteins/genetics , RNA, Messenger/biosynthesis , Receptor, Interferon alpha-beta , Receptors, Interferon/geneticsABSTRACT
CTLs recognize peptide epitopes which are proteolytically generated by the proteasome and presented on MHC class I molecules. According to the defective ribosomal product (DRiP) hypothesis, epitopes originate from newly synthesized polypeptides which are degraded shortly after their translation. The DRiP hypothesis would explain how epitopes can be generated from long-lived proteins. We examined whether neosynthesis is required for presentation of the immunodominant epitope NP118 of the lymphocytic choriomeningitis virus nucleoprotein, which has a half-life of >3 days. Two days after nucleoprotein biosynthesis was terminated in a tetracycline-regulated transfectant, the presentation of the NP118 epitope ceased. This indicates that NP118 epitopes are generated from newly synthesized nucleoproteins rather than from the long-lived pool of nucleoproteins in the cell. Therefore, the lymphocytic choriomeningitis virus nucleoprotein is the first substrate for which a major prediction of the DRiP hypothesis, namely the requirement for neosynthesis, is shown to hold true.
Subject(s)
Antigen Presentation , Epitopes, T-Lymphocyte , Nucleoproteins/biosynthesis , Peptide Fragments/biosynthesis , Animals , Mice , Mice, Inbred BALB C , Nucleoproteins/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , TransfectionABSTRACT
FAT10 is a ubiquitin-like protein that is encoded in the major histocompatibility complex class I locus and is synergistically inducible with interferon-gamma and tumor necrosis factor alpha. The molecule consists of two ubiquitin-like domains in tandem arrangement and bears a conserved diglycine motif at its carboxyl terminus commonly used in ubiquitin-like proteins for isopeptide linkage to conjugated proteins. We investigated the function of FAT10 by expressing murine FAT10 in a hemagglutinin-tagged wild type form as well as a diglycine-deficient mutant form in mouse fibroblasts in a tetracycline-repressible manner. FAT10 expression did not affect major histocompatibility complex class I cell surface expression or antigen presentation. However, we found that wild type but not mutant FAT10 caused apoptosis within 24 h of induction in a caspase-dependent manner as indicated by annexin V cell surface staining and DNA fragmentation. Wild type FAT10, but not its diglycine mutant, was covalently conjugated to thus far unidentified proteins, indicating that specific FAT10 activating and conjugating enzymes must be operative in unstimulated fibroblasts. Because FAT10 expression causes apoptosis and is inducible with tumor necrosis factor alpha, it may be functionally involved in the programmed cell death mediated by this cytokine.
Subject(s)
Apoptosis/physiology , Carrier Proteins/metabolism , Ubiquitins , Animals , Base Sequence , Carrier Proteins/genetics , Carrier Proteins/physiology , Cell Line , DNA Primers , Down-Regulation , Fluorescent Antibody Technique , Gene Expression Regulation , Histocompatibility Antigens Class I/metabolism , Mice , Polymerase Chain Reaction , Protein BindingABSTRACT
Hepatitis C virus (HCV) infection takes a chronic course in the majority of patients. The mechanisms underlying the evasion of the host immune response and viral persistence are poorly understood. In this context, we investigated interactions of HCV proteins with major histocompatibility complex (MHC) class I processing and presentation pathways using cell lines that allow the tetracycline-regulated expression of viral structural and nonstructural proteins. These well-characterized inducible cell lines were found to efficiently process and present endogenously synthesized HCV proteins via MHC class I. Functional MHC class I cell-surface expression and intracellular proteasome activity were not affected by the expression of HCV proteins. These results suggest that viral evasion of the host immune response does not involve interactions of HCV with MHC class I processing and presentation. Other mechanisms, such as interference with the interferon system, may be operative in HCV infection, leading to viral persistence.
Subject(s)
Hepacivirus/metabolism , Histocompatibility Antigens Class I/metabolism , Protein Processing, Post-Translational , Viral Proteins/metabolism , Cell Membrane/metabolism , Cysteine Endopeptidases/physiology , HLA Antigens/classification , HLA-A2 Antigen/immunology , Humans , Intracellular Membranes/physiology , Multienzyme Complexes/physiology , Proteasome Endopeptidase Complex , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/physiology , Tumor Cells, Cultured , Viral Proteins/physiologyABSTRACT
When cells are stimulated with the cytokines IFN-gamma or TNF-alpha, the synthesis of three proteasome subunits LMP2 (beta1i), LMP7 (beta5i), and MECL-1 (beta2i) is induced. These subunits replace the three subunits delta (beta1), MB1 (beta5), and Z (beta2), which bear the catalytically active sites of the proteasome, during proteasome neosynthesis. The cytokine-induced exchanges of three active site subunits of a complex protease is unprecedented in biology and one may expect a strong functional driving force for this system to evolve. These cytokine-induced replacements of proteasome subunits are believed to favour the production of peptide ligands of major histocompatibility complex (MHC) class I molecules for the stimulation of cytotoxic T cells. Although the peptide production by constitutive proteasomes is able to maintain peptide-dependent MHC class I cell surface expression in the absence of LMP2 and LMP7, these subunits were recently shown to be pivotal for the generation or destruction of several unique epitopes. In this review we discuss the recent data on LMP2/LMP7/MECL-1-dependent epitope generation and the functions of each of these subunit exchanges. We propose that these subunit exchanges have evolved not only to optimize class I peptide loading but also to generate LMP2/LMP7/MECL-1-dependent epitopes in inflammatory sites which are not proteolytically generated in uninflamed tissues. This difference in epitope generation may serve to better stimulate T cells in the sites of an ongoing immune response and to avoid autoimmunity in uninflamed tissues.
Subject(s)
Cysteine Endopeptidases/biosynthesis , Interferon-gamma/immunology , Multienzyme Complexes/biosynthesis , Protein Biosynthesis , Animals , Antigen Presentation , Binding Sites/physiology , Cysteine Endopeptidases/drug effects , Cysteine Endopeptidases/metabolism , Cytokines/pharmacology , Genes, MHC Class I , Humans , Interferon-gamma/pharmacology , Peptide Hydrolases/biosynthesis , Peptides/chemistry , Peptides/metabolism , Proteasome Endopeptidase Complex , Protein Subunits , Proteins/drug effects , T-Lymphocytes/enzymology , T-Lymphocytes/immunologyABSTRACT
The proteasome is the main provider of peptide ligands for major histocompatibility complex class I molecules. During an immune response to pathogens, the proinflammatory cytokine interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha are released, which induce the proteasome subunits LMP2, LMP7, and MECL-1. These replace the constitutively expressed active site subunits of the proteasome (delta, MB1, and Z) leading to a marked change in the cleavage preference of the proteasome and the production of T-cell epitopes. Proteasome activity is further changed by the IFN-gamma-mediated induction of the proteasome regulator PA28alpha/beta and the downregulation of PA28gamma. Why such an extensive exchange of proteasome active site subunits and regulators occurs is still poorly understood. In this article we discuss recent insights in the structural consequences of proteasome reorganization and their effects on epitope generation and shaping of the cytotoxic immune response. Moreover, we review the latest data on how the ubiquitin pathway targets protein antigens for peptide processing and discuss the potential of proteasome inhibitors for the modulation of antigen presentation.
Subject(s)
Antigen Presentation/immunology , Cysteine Endopeptidases/immunology , Multienzyme Complexes/immunology , Amino Acid Sequence , Animals , Humans , Interferon-gamma/immunology , Molecular Sequence Data , Multienzyme Complexes/antagonists & inhibitors , Proteasome Endopeptidase Complex , Signal Transduction/immunology , Structure-Activity Relationship , Ubiquitin/immunology , Virus Diseases/immunologyABSTRACT
Myeloid antigen-presenting cells (APC) are known to cross-present exogenous antigen on major histocompatibility class I molecules to CD8+ T cells and thereby induce protective immunity against infecting microorganisms. Here we report that liver sinusoidal endothelial cells (LSEC) are organ-resident, non-myeloid APC capable of cross-presenting soluble exogenous antigen to CD8+ T cells. Though LSEC employ similar molecular mechanisms for cross-presentation as dendritic cells, the outcome of cross-presentation by LSEC is CD8+ T cell tolerance rather than immunity. As uptake of circulating antigens into LSEC occurs efficiently in vivo, it is likely that cross-presentation by LSEC contributes to CD8+ T cell tolerance observed in situations where soluble antigen is present in the circulation.
Subject(s)
Antigen Presentation , CD8-Positive T-Lymphocytes/immunology , Endothelium/immunology , Immune Tolerance , Liver/immunology , Animals , Antigen-Presenting Cells , Antigens/immunology , Bone Marrow Cells/immunology , Endothelium/cytology , Liver/cytology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Ovalbumin/immunologyABSTRACT
Immunotherapy of prostate cancer (CaP) may be a promising novel treatment option for the management of advanced CaP. However, the lack of suitable tumor antigens remains a major obstacle for the rational design of vaccines. To characterize potential CaP antigens, we determined the mRNA expression of the prostate-specific genes C1, C2, C5, PAGE-1, and prostate stem cell antigen (PSCA) in hormone-refractory CaP, benign prostatic hyperplasia, CaP cell lines, and CaP specimens. Among these gene products, only expression of PSCA appears to be retained in the majority of advanced CaP samples, as shown by reverse transcription-PCR analyses. Peptide fragments of PSCA presented in the context of major histocompatibility molecules could serve as recognition targets for CD8 T cells, provided these lymphocytes were not clonally deleted or peripherally tolerized. Our goal was to determine whether the human T-cell repertoire could recognize PSCA-derived peptide epitopes in the context of a common class I allele, HLA-A0201. Of nine peptides that, according to HLA-A0201 binding motifs, were candidate ligands of A0201 class I molecules, three peptides were able to stabilize HLA-A0201 molecules on the cell surface. One of the latter peptides, encompassing amino acid residues 14-22, was capable of generating a PSCA-specific T-cell response in a human lymphocyte culture from a patient with metastatic CaP. PSCA-specific CTLs recognized peptide-pulsed targets as well as three prostate carcinoma lines in cytotoxicity assays, indicating that this peptide could be endogenously processed. In conclusion, our findings establish PSCA as a potential target for antigen-specific, T cell-based immunotherapy of prostate carcinoma.
Subject(s)
Antigens, Neoplasm/immunology , Immunotherapy, Active/methods , Membrane Glycoproteins/immunology , Neoplasm Proteins/immunology , Prostatic Neoplasms/immunology , Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/genetics , Cancer Vaccines/immunology , Epitopes, T-Lymphocyte/immunology , GPI-Linked Proteins , Gene Expression , HLA-A Antigens/genetics , HLA-A Antigens/immunology , HLA-A Antigens/metabolism , Humans , Male , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Organ Specificity , Peptide Fragments/immunology , Peptide Fragments/metabolism , Prostatic Hyperplasia/immunology , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/therapy , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes, Cytotoxic/immunology , Tumor Cells, CulturedABSTRACT
The proteasome is a large protease complex that generates most of the peptide ligands of MHC class I molecules either in their final form or in the form of N-terminally extended precursors. Upon the stimulation of cells with IFN-gamma, three constitutively expressed subunits of the 20S proteasome are replaced by the inducible subunits LMP2 (low-molecular mass polypeptide 2), LMP7, and MECL-1 (multicatalytic endopeptidase complex-like-1) to form so-called immunoproteasomes. We show in this study that overexpression of these three subunits in triple transfectants led to a marked enhancement in the H-2Ld-restricted presentation of the immunodominant nonameric epitope NP118, which is derived from the nucleoprotein (NP) of lymphocytic choriomeningitis virus. Overexpression of the alpha and beta subunits of the IFN-gamma-inducible proteasome regulator PA28, in contrast, did not have a comparable effect. In vitro, immunoproteasomes as compared with constitutive proteasomes generated higher amounts of 11- and 12-mer fragments containing the NP118 epitope. These are likely to be cytosolic precursors of NP118, as a proline anchor residue in the second position of NP118 may interfere with TAP-mediated transport of the nonameric epitope itself. In conclusion, we provide evidence that up-regulation of the three inducible subunits, LMP2, LMP7, and MECL-1, can result in a marked improvement of Ag presentation and that, depending on the epitope, PA28 and immunoproteasomes may differentially affect Ag processing.
Subject(s)
Adjuvants, Immunologic/biosynthesis , Antigen Presentation/immunology , Cysteine Endopeptidases/biosynthesis , Epitopes, T-Lymphocyte/metabolism , Immunodominant Epitopes/metabolism , Lymphocytic choriomeningitis virus/immunology , Multienzyme Complexes/biosynthesis , Protein Biosynthesis , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/physiology , Amino Acid Sequence , Animals , Antigen Presentation/genetics , Autoantigens , Cell Line , Cysteine Endopeptidases/genetics , Cysteine Endopeptidases/immunology , Cytosol/immunology , Cytosol/metabolism , Epitopes, T-Lymphocyte/genetics , H-2 Antigens/biosynthesis , H-2 Antigens/genetics , Histocompatibility Antigen H-2D , Hybridomas , Immunodominant Epitopes/genetics , Lymphocytic choriomeningitis virus/genetics , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Multienzyme Complexes/genetics , Multienzyme Complexes/immunology , Nucleoproteins/biosynthesis , Nucleoproteins/genetics , Nucleoproteins/immunology , Nucleoproteins/metabolism , Peptide Fragments/biosynthesis , Peptide Fragments/genetics , Peptide Fragments/immunology , Peptide Fragments/metabolism , Proteasome Endopeptidase Complex , Protein Precursors/biosynthesis , Protein Precursors/genetics , Proteins/genetics , Proteins/immunology , Transfection , Viral Proteins/biosynthesis , Viral Proteins/genetics , Viral Proteins/immunology , Viral Proteins/metabolismABSTRACT
The complete inhibition of proteasome activities interferes with the production of most MHC class I peptide ligands as well as with cellular proliferation and survival. In this study we have investigated how partial and selective inhibition of the chymotrypsin-like activity of the proteasome by the proteasome inhibitors lactacystin or epoxomicin would affect Ag presentation. At 0.5-1 microM lactacystin, the presentation of the lymphocytic choriomeningitis virus-derived epitopes NP118 and GP33 and the mouse CMV epitope pp89-168 were reduced and were further diminished in a dose-dependent manner with increasing concentrations. Presentation of the lymphocytic choriomeningitis virus-derived epitope GP276, in contrast, was markedly enhanced at low, but abrogated at higher, concentrations of either lactacystin or epoxomicin. The inhibitor-mediated effects were thus epitope specific and did not correlate with the degradation rates of the involved viral proteins. Although neither apoptosis induction nor interference with cellular proliferation was observed at 0.5-1 microM lactacystin in vivo, this concentration was sufficient to alter the fragmentation of polypeptides by the 20S proteasome in vitro. Our results indicate that partial and selective inhibition of proteasome activity in vivo is a valid approach to modulate Ag presentation, with potential applications for the treatment of autoimmune diseases and the prevention of transplant rejection.
Subject(s)
Acetylcysteine/analogs & derivatives , Antigen Presentation/drug effects , Antigens, Viral , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Down-Regulation/immunology , Multienzyme Complexes/metabolism , Up-Regulation/immunology , Viral Proteins , Acetylcysteine/pharmacology , Acetylcysteine/toxicity , Amino Acid Sequence , Animals , Apoptosis/drug effects , Cell Division/drug effects , Cell Line , Cysteine Proteinase Inhibitors/toxicity , Dose-Response Relationship, Immunologic , Down-Regulation/drug effects , Glycoproteins/metabolism , Humans , Hybridomas/immunology , Hybridomas/metabolism , Hydrolysis/drug effects , Lymphocyte Activation/drug effects , Lymphocytic choriomeningitis virus/drug effects , Lymphocytic choriomeningitis virus/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Molecular Sequence Data , Nucleoproteins/metabolism , Oligopeptides/pharmacology , Oligopeptides/toxicity , Peptide Fragments/immunology , Peptide Fragments/metabolism , Proteasome Endopeptidase Complex , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , Tumor Cells, Cultured , Ubiquitins/metabolism , Up-Regulation/drug effectsABSTRACT
The 20 S proteasome is an endoprotease complex that preferentially cleaves peptides C-terminal of hydrophobic, basic, and acidic residues. Recently, we showed that these specific activities, classified as chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide-hydrolyzing (PGPH) activity, are differently affected by Ritonavir, an inhibitor of human immunodeficiency virus-1 protease. Ritonavir competitively inhibited the chymotrypsin-like activity, whereas the trypsin-like activity was enhanced. Here we demonstrate that the Ritonavir-mediated up-regulation of the trypsin-like activity is not affected by specific active site inhibitors of the chymo-trypsin-like and PGPH activity. Moreover, we show that the mutual regulation of chymotrypsin-like and PGPH activities by their substrates as described previously by a "cyclical bite-chew" model is not affected by selective inhibitors of the respective active sites. These data challenge the bite-chew model and suggest that effectors of proteasome activity can act by binding to non-catalytic sites. Accordingly, we propose a kinetic "two-site modifier" model that assumes that the substrate (or effector) may bind to an active site as well as to a second non-catalytic modifier site. This model appears to be valid as it describes the complex kinetic effects of Ritonavir very well. Since Ritonavir partially inhibits major histocompatibility complex class I restricted antigen presentation, the postulated modifier site may be required to coordinate the active centers of the proteasome for the production of class I peptide ligands.
Subject(s)
Cysteine Endopeptidases/chemistry , Multienzyme Complexes/chemistry , Animals , Binding Sites , Cysteine Endopeptidases/metabolism , Enzyme Activation , Humans , Hydrolysis , Liver/enzymology , Mice , Multienzyme Complexes/metabolism , Proteasome Endopeptidase Complex , Substrate SpecificitySubject(s)
Antigen Presentation , Hybridomas/immunology , Lymphocytic choriomeningitis virus/immunology , T-Lymphocytes/immunology , Amino Acid Sequence , Animals , Antigens, Viral/genetics , Histocompatibility Antigens Class I , Lac Operon , Lymphocytic choriomeningitis virus/genetics , Mice , T-Lymphocytes, Cytotoxic/immunologyABSTRACT
PA28alpha/beta is a regulatory complex of the 20S proteasome which consists of two IFN-gamma inducible subunits. Both subunits, alpha and beta, contribute equally to the formation of hexa- or heptameric rings which can associate with the 20S proteasome. Previously, we have shown that overexpression of the PA28alpha subunit enhanced the MHC class I-restricted presentation of two viral epitopes and that purified PA28alpha/beta accelerated T cell epitope generation by the 20S proteasome in vitro, indicating a role for PA28alpha/beta in antigen presentation. This conclusion was recently confirmed in PA28beta gene targeted mice which were severely deficient in MHC class I-restricted antigen presentation. These mice displayed a defect in the assembly of immunoproteasomes, suggesting that a lack of the proteasome subunits LMP2, LMP7, and MECL-1 may account for the deficiency in antigen presentation. In this study we investigated whether the effect of PA28alpha/beta on antigen presentation is dependent on a change of proteasome subunit composition. We have analyzed the assembly and subunit composition of proteasomes in fibroblast transfectants overexpressing both, alpha and beta subunits of PA28. In these transfectants we found a marked enhancement in the presentation of the immunodominant H-2Ld-restricted pp89 epitope of murine cytomegalovirus, although the 20S proteasome composition was the same as in recipient cells. We, therefore, conclude that PA28alpha/beta can enhance antigen processing independently of changes in 20S proteasome subunit composition or assembly.
Subject(s)
Antigen Presentation , Cysteine Endopeptidases/physiology , Multienzyme Complexes/physiology , Proteins/physiology , Animals , Autoantigens , Cysteine Endopeptidases/chemistry , Interferon-gamma/pharmacology , Mice , Mice, Inbred BALB C , Multienzyme Complexes/chemistry , Proteasome Endopeptidase Complex , Protein Subunits , TransfectionABSTRACT
For several decades, approaches utilizing nonspecific immune stimulants have provided evidence that the immune system, when properly activated, may eradicate cancer cells. However, it was only after the identification of the first human tumor-associated antigen, less than a decade ago, that development of specific vaccination procedures for cancer patients became feasible. Recent insights into the pivotal role of dendritic cells (DCs) for initiation and regulation of immune responses have allowed the design of DC-based tumor vaccination trials. In addition, the development of methods to raise large numbers of DCs from peripheral blood monocytes has paved the way for their clinical application. Tumor-specific vaccination utilizing antigen-loaded autologous DCs, has become practical and applicable to patients and may lead to vigorous antitumor responses. This review outlines recent progress, obstacles still to be overcome, and the future potential of DC-based vaccination. Copyright 2000 S. Karger GmbH, Freiburg
ABSTRACT
A means of regulating the fate of intracellular proteins is their covalent conjugation to ubiquitin-like proteins. A recently discovered ubiquitin-like protein is called "diubiquitin" because it consists of two ubiquitin-like domains in head-to-tail arrangement. Human diubiquitin is encoded at the telomeric end of the MHC class I locus and was previously found to be expressed in dendritic cells and mature B cells. We have extended the expression analysis of diubiquitin by reverse transcriptase-PCR and Northern blotting in primary endothelial cells and human cancer cell lines derived from nine different tissues. Diubiquitin expression was found to be generally and synergistically inducible with the cytokines IFN-gamma and TNF-alpha but not with IFN-alpha. Diubiquitin mRNA expression was induced within 2 h after cytokine stimulation and was independent of protein neosynthesis but dependent on proteasome activity. The mouse homologue of diubiquitin which is also encoded in the MHC class I locus was likewise induced with IFN-gamma and TNF-alpha. A general and synergistic induction with IFN-gamma and TNF-alpha suggests that diubiquitin may exert its functions in antigen presentation or other cellular processes controlled by these two cytokines.
Subject(s)
Antiviral Agents/pharmacology , Interferon-gamma/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Ubiquitins/biosynthesis , Amino Acid Sequence , Animals , Drug Synergism , Gene Expression Regulation/drug effects , Humans , Mice , Molecular Sequence Data , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Sequence Alignment , Tumor Cells, Cultured , Ubiquitins/geneticsABSTRACT
Dendritic cells (DC) are highly specialized professional antigen presenting cells which are pivotal for the initiation and control of the cytotoxic T cell response. Upon stimulation by cytokines, bacteria, or CD40L DC undergo a maturation process from an antigen-receptive state to a state of optimal stimulation of T cells. We investigated the composition of proteasomes of DC derived from human peripheral blood monocytes before and after stimulation by CD40L, LPS, or proinflammatory cytokines (TNF-alpha + IL-6 + IL-1beta). Immunoprecipitation of proteasomes and analysis on two-dimensional gels revealed that during maturation the inducible proteasome subunits LMP2, LMP7, and MECL-1 are up-regulated and that the neosynthesis of proteasomes is switched exclusively to the production of immunoproteasomes containing these subunits. The proteasome regulator PA28 is markedly up-regulated in mature DC and in addition a so - far unidentified 21-kDa protein co-precipitates with the proteasome in LPS - stimulated DC. These changes in proteasome composition may be functionally linked to special properties of DC like MHC class I up-regulation or cross-priming. Our findings imply that the spectrum of class I-bound peptides may change after DC maturation which could be relevant for the design of DC - based vaccines.
Subject(s)
Cysteine Endopeptidases/immunology , Dendritic Cells/immunology , Enzyme Activators/immunology , Multienzyme Complexes/immunology , Muscle Proteins , Proteins/immunology , Antigen Presentation/immunology , Cell Differentiation/immunology , Cells, Cultured , Cysteine Endopeptidases/genetics , Dendritic Cells/cytology , Gene Expression Regulation/immunology , Humans , Multienzyme Complexes/genetics , Proteasome Endopeptidase Complex , Proteins/genetics , Up-Regulation/immunologyABSTRACT
The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may exert a direct effect on the immune system unrelated to inhibition of the human immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major histocompatibility complex class I restricted presentation of several viral antigens at therapeutically relevant concentrations (5 microM). In search of a molecular target we found that Ritonavir inhibited the chymotrypsin-like activity of the proteasome whereas the tryptic activity was enhanced. In this study we kinetically analyzed how Ritonavir modulates proteasome activity and what consequences this has on cellular functions of the proteasome. Ritonavir is a reversible effector of proteasome activity that protected the subunits MB-1 (X) and/or LMP7 from covalent active site modification with the vinyl sulfone inhibitor(125)I-NLVS, suggesting that they are the prime targets for competitive inhibition by Ritonavir. At low concentrations of Ritonavir (5 microM) cells were more sensitive to canavanine but proliferated normally whereas at higher concentrations (50 microM) protein degradation was affected, and the cell cycle was arrested in the G(1)/S phase. Ritonavir thus modulates antigen processing at concentrations at which vital cellular functions of the proteasome are not yet severely impeded. Proteasome modulators may hence qualify as therapeutics for the control of the cytotoxic immune response.